Genprex Inc. Stock News

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies AUSTIN, Texas , March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:

Genprex Inc. said it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for gross proceeds of approximately $4 million.

Genprex (NASDAQ: GNPX ) stock is on the move Thursday after providing an update on a study of its diabetes treatment. That positive news comes from a trial of gene therapy for the treatment of Type 1

Genprex, Inc. (NASDAQ:GNPX) has announced that data highlighting the potential of its gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh

Gene-based therapy company Genprex, Inc (NASDAQ:GNPX) has caught the eye of research firm Dawson James, which has initiated coverage with a Buy rating and $3 target price on the stock. Genprex is an

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. Spruce Biosciences, Inc. (NASDAQ: SPRB) shares jumped 100.8%

Genprex, Inc. (NASDAQ:GNPX) told investors it has entered into an exclusive license agreement with the University of Pittsburgh, granting the company a worldwide, exclusive license to a patent applic

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sl

Genprex, Inc. (NASDAQ:GNPX) revealed that it has struck an agreement with the University of Pittsburgh for a worldwide, exclusive license to some patent applications and a worldwide, non-exclusive li

Genprex, Inc. (NASDAQ:GNPX) has announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX ), a clini

Corporate and Clinical Presentations to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 8, 2022 /PRNewswire/ --  Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clin

Analysts at Noble Capital have reiterated an 'Outperform' rating and $5 price target on Genprex Inc which recently announced that the first cohort from its Phase 1/2 Acclaim-1 trial in non-small cell

Genprex, Inc. (NASDAQ:GNPX) said the company has been issued a patent that covers using REQORSA Immunogene Therapy in conjunction with immune checkpoint inhibitors for lung cancer. Thomas Gallagher, s